Modulation Of Apolipoprotein Ciii (Apociii) Expression - EP2701713

The patent EP2701713 was granted to Ionis Pharmaceuticals on Feb 7, 2018. The application was originally filed on Apr 27, 2012 under application number EP12776385A. The patent is currently recorded with a legal status of "Revoked".

EP2701713

IONIS PHARMACEUTICALS
Application Number
EP12776385A
Filing Date
Apr 27, 2012
Status
Revoked
Jul 19, 2019
Grant Date
Feb 7, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

PFIZERNov 7, 2018MASCHIOADMISSIBLE
STRAWMANNov 7, 2018MORGANADMISSIBLE

Patent Citations (43) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS20070989574-
DESCRIPTIONUS20080026995-
DESCRIPTIONUS20080026998-
DESCRIPTIONUS20080056564-
DESCRIPTIONUS20080086231-
DESCRIPTIONUS20080097787-
DESCRIPTIONUS20080099844-
DESCRIPTIONWO1998DK00393-
DESCRIPTIONUS2004171570
DESCRIPTIONUS2004208856
DESCRIPTIONUS2005130923
DESCRIPTIONUS2006264395
DESCRIPTIONUS2008039618
DESCRIPTIONUS2009012281
DESCRIPTIONUS6268490
DESCRIPTIONUS6525191
DESCRIPTIONUS6670461
DESCRIPTIONUS6770748
DESCRIPTIONUS6794499
DESCRIPTIONUS7034133
DESCRIPTIONUS7053207
DESCRIPTIONUS7399845
DESCRIPTIONUS7427672
DESCRIPTIONUS7547684
DESCRIPTIONUS7598227
DESCRIPTIONUS7696345
DESCRIPTIONUS7750141
DESCRIPTIONWO03004602
DESCRIPTIONWO2004093783
DESCRIPTIONWO2004106356
DESCRIPTIONWO2005021570
DESCRIPTIONWO2007134181
DESCRIPTIONWO2008101157
DESCRIPTIONWO2008150729
DESCRIPTIONWO2008154401
DESCRIPTIONWO2009006478
DESCRIPTIONWO9414226
DESCRIPTIONWO9839352
DESCRIPTIONWO9914226
INTERNATIONAL-SEARCH-REPORTUS2004224304
INTERNATIONAL-SEARCH-REPORTUS2006264395
OPPOSITIONWO2004093783
SEARCHWO2010107838

Non-Patent Literature (NPL) Citations (117) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ALBAEK ET AL., J. ORG. CHEM., (2006), vol. 71, pages 7731 - 7740-
DESCRIPTION- ALTMANN ET AL., BIOCHEM. SOC. TRANS., (1996), vol. 24, pages 630 - 637-
DESCRIPTION- ALTMANN ET AL., CHIMIA, (1996), vol. 50, pages 168 - 176-
DESCRIPTION- ALTMANN ET AL., NUCLEOSIDES NUCLEOTIDES, (1997), vol. 16, pages 917 - 926-
DESCRIPTION- ALTSCHUL ET AL., J. MOL. BIOL., (1990), vol. 215, pages 403 - 410-
DESCRIPTION- ARCH. INT. MED., (1988), vol. 148, pages 36 - 39-
DESCRIPTION- AVIRAM, M; ROSENBLAT, M, CURR. OPIN. LIPIDOL., (2005), vol. 16, pages 393 - 399-
DESCRIPTION- BAKER ET AL., J. BIOL. CHEM., (1997), vol. 272, pages 11944 - 12000-
DESCRIPTION- BANSAL ET AL., JAMA, (2007), vol. 298, pages 309 - 16-
DESCRIPTION- BARTER P.J ET AL., ARTHERIOSCLER. THROMB. VASE. BIOL., (2003), vol. 23, pages 160 - 167-
DESCRIPTION- BLIGH EG; DYER WJ., CAN J BIOCHEM PHYSIOL, (1959), vol. 37, pages 911 - 917-
DESCRIPTION- BLIGH, E.G.; DYER, W.J, CAN. J. BIOCHEM. PHYSIOL., (1959), vol. 37, pages 911 - 917-
DESCRIPTION- BLIGH, E.G.; DYER, W.J., CAN. J. BIOCHEM. PHYSIOL., (1959), vol. 37, pages 911 - 917-
DESCRIPTION- BLIGH, E.G; DYER, W.J., CAN. J. BIOCHEM. PHYSIOL., (1959), vol. 37, pages 911 - 917-
DESCRIPTION- BRAASCH ET AL., CHEM. BIOL., (2001), vol. 8, pages 1 - 7-
DESCRIPTION- BRISSON ET AL., PHARMACOGENET GENOM, (2010), vol. 20, pages 742 - 747-
DESCRIPTION- CAMPOS ET AL., J. LIPID RES., (2001), vol. 42, pages 1239 - 1249-
DESCRIPTION- CATAPANO ET AL., ATHEROSCLEROSIS, (2011), vol. 217S, pages S1 - S44-
DESCRIPTION- CHAIT ET AL., ADV INTERN MED., (1992), vol. 37, pages 249 - 73-
DESCRIPTION- CHAN ET AL., CLIN. CHEM., (2002), pages 278 - 283-
DESCRIPTION- CHAN ET AL., INT J CLIN PRACT, (2008), vol. 62, pages 799 - 809-
DESCRIPTION- CHATTOPADHYAYA ET AL., J. ORG. CHEM., (2009), vol. 74, pages 118 - 134-
DESCRIPTION- CIRCULATION, (2002), vol. 106, pages 3143 - 421-
DESCRIPTION- DAMMERMAN ET AL., PROC. NATL. ACAD. SCI. U. S. A., (1993), vol. 90, pages 4562 - 4566-
DESCRIPTION- DAVIDSSON ET AL., J. LIPID RES., (2005), vol. 46, pages 1999 - 2006-
DESCRIPTION- DE SILVA ET AL., J. BIOL. CHEM., (1994), vol. 269, pages 2324 - 2335-
DESCRIPTION- DIABETES CARE, (2008), vol. 31, pages S12 - S54-
DESCRIPTION- ELAYADI ET AL., CURR. OPINION INVEST. DRUGS, (2001), vol. 2, pages 558 - 561-
DESCRIPTION- FERN ET AL., J CLIN PATHOL, (2008), vol. 61, pages 1174 - 118-
DESCRIPTION- FREDRICKSON ET AL., NEW ENG J MED, (1967), vol. 276, no. 1, pages 34 - 42-
DESCRIPTION- FREDRICKSON; LEE, CIRCULATION, (1965), vol. 31, pages 321 - 327-
DESCRIPTION- FREIER ET AL., NUCLEIC ACIDS RESEARCH, (1997), vol. 25, no. 22, pages 4429 - 4443-
DESCRIPTION- FRIEDEN ET AL., NUCLEIC ACIDS RESEARCH, (2003), vol. 21, pages 6365 - 6372-
DESCRIPTION- GASTALDELLI ET AL., J APPL. PHYSIOL, (1999), vol. 87, pages 1813 - 1822-
DESCRIPTION- GAUDET ET AL., ATHEROSCLEROSIS SUPPLEMENTS, (2010), vol. 11, pages 55 - 60-
DESCRIPTION- GAUTSCHI ET AL., J. NATL. CANCER INST., (200103), vol. 93, pages 463 - 471-
DESCRIPTION- GERRITSEN ET AL., J. LIPID RES., (2005), vol. 46, pages 1466 - 1473-
DESCRIPTION- GORDON ET AL., AM. J. MED., (1977), vol. 62, pages 707 - 714-
DESCRIPTION- HAVEL; KANE, The Metabolic & Molecular Bases of Inherited Disease, MCGRAW-HILL, (2001), pages 2705 - 16-
DESCRIPTION- HEGELE ET AL., HUM MOL GENET, (2009), vol. 18, pages 4189 - 4194-
DESCRIPTION- HEGELE; POLLEX, MOL CELL BIOCHEM, (2009), vol. 326, pages 35 - 43-
DESCRIPTION- HERTZ ET AL., J. BIOL. CHEM., (1995), vol. 270, pages 13470 - 13475-
DESCRIPTION- ITO ET AL., SCIENCE, (1990), vol. 249, pages 790 - 793-
DESCRIPTION- JAMA, (2001), vol. 285, pages 2486 - 2497-
DESCRIPTION- JONES, L.J. ET AL., ANALYTICAL BIOCHEMISTRY, (1998), vol. 265, pages 368 - 374-
DESCRIPTION- JONG ET AL., J. LIPID RES., (2001), vol. 42, pages 1578 - 1585-
DESCRIPTION- KARATHANASIS, PROC. NATL. ACAD. SCI. U. S. A., (1985), vol. 82, pages 6374 - 6378-
DESCRIPTION- KARDASSIS ET AL., BIOCHEMISTRY, (2002), vol. 41, pages 1217 - 1228-
DESCRIPTION- KARDASSIS ET AL., J. BIOL. CHEM., (2000), vol. 275, pages 41405 - 41414-
DESCRIPTION- KASHYAP, AM. J. CARDIOL, (1998), vol. 82, pages 42U - 48U-
DESCRIPTION- KOSHKIN ET AL., TETRAHEDRON, (1998), vol. 54, pages 3607 - 3630-
DESCRIPTION- KUMAR ET AL., BIOORG. MED. CHEM. LETT., (1998), vol. 8, pages 2219 - 2222-
DESCRIPTION- LEE ET AL., ARTERIOSCLER THROMB VASC BIOL., (2003), vol. 23, pages 853 - 858-
DESCRIPTION- LEUMANN, BIOORG. MED. CHEM., (2002), vol. 10, pages 841 - 854-
DESCRIPTION- LEVY-WILSON ET AL., DNA, (1984), vol. 3, pages 359 - 364-
DESCRIPTION- LI ET AL., J. CLIN. INVEST., (1995), vol. 96, pages 2601 - 2605-
DESCRIPTION- MAEDA ET AL., J. BIOL. CHEM., (1994), vol. 269, pages 23610 - 23616-
DESCRIPTION- MAEDA ET AL., J. LIPID RES., (1987), vol. 28, pages 1405 - 1409-
DESCRIPTION- MAHER; DOLNICK, NUC. ACID. RES., (1988), vol. 16, pages 3341 - 3358-
DESCRIPTION- MARTIN, HELV. CHIM. ACTA, (1995), vol. 78, pages 486 - 504-
DESCRIPTION- MAUGER ET AL., J. LIPID RES., (2006), vol. 47, pages 1212 - 1218-
DESCRIPTION- MENDIVIL ET AL., CIRCULATION, (2011), vol. 124, pages 2065 - 2072-
DESCRIPTION- MITTENDORFER ET AL., DIABETES, (2003), vol. 52, pages 1641 - 1648-
DESCRIPTION- NORDESTGAARD ET AL., ARTERIOSCLEROSIS, (1988), vol. 8, pages 421 - 428-
DESCRIPTION- NORDESTGAARD ET AL., JAMA, (2007), vol. 298, pages 299 - 308-
DESCRIPTION- NORDESTGAARD ET AL., J LIPID RES, (1988), vol. 29, pages 1491 - 1500-
DESCRIPTION- NORMAND-LAUZIERE ET AL., PLOS. ONE, (2010), vol. 5, page E10956-
DESCRIPTION- NORMAND-LAUZIERE ET AL., PLOS. ONE, (2010), vol. 5, page EL0956-
DESCRIPTION- OGAMI ET AL., J. BIOL. CHEM., (1991), vol. 266, pages 9640 - 9646-
DESCRIPTION- OLIVIERI ET AL., J. LIPID RES., (2002), vol. 43, pages 1450 - 1457-
DESCRIPTION- ONAT, ATHEROSCLEROSIS, (2003), vol. 168, pages 81 - 89-
DESCRIPTION- OOI ET AL., CLIN. SCI., (2008), vol. 114, pages 611 - 624-
DESCRIPTION- ORUM ET AL., CURR. OPINION MOL. THER., (2001), vol. 3, pages 239 - 243-
DESCRIPTION- PETERSEN ET AL., N ENGL J MED, (2010), vol. 362, pages 1082 - 1089-
DESCRIPTION- PETERSEN K.F ET AL., N ENGL J MED, (2010), vol. 362, pages 1082 - 1089-
DESCRIPTION- PETERSEN K.F. ET AL., N ENGL J MED, (2010), vol. 362, pages 1082 - 1089-
DESCRIPTION- POLLIN ET AL., SCIENCE, (2008), vol. 322, pages 1702 - 1705-
DESCRIPTION- PROTTER ET AL., DNA, (1984), vol. 3, pages 449 - 456-
DESCRIPTION- RASPE ET AL., J. LIPID RES., (2002), vol. 43, pages 2172 - 2179-
DESCRIPTION- SACKS ET AL., CIRCULATION, (2000), vol. 102, pages 1886 - 1892-
DESCRIPTION- SANGHVI, Y.S., CROOKE, S.T. AND LEBLEU, B., Antisense Research and Applications, CRC PRESS, (1993), pages 276 - 278-
DESCRIPTION- SCHOONJANS ET AL., FEBS LETT., (1999), vol. 452, pages 160 - 164-
DESCRIPTION- SHACHTER, CURR. OPIN. LIPIDOL., (2001), vol. 12, pages 297 - 304-
DESCRIPTION- SHARPE ET AL., NUCLEIC ACIDS RES., (1984), vol. 12, pages 3917 - 3932-
DESCRIPTION- SINGH ET AL., CHEM. COMMUN., (1998), vol. 4, pages 455 - 456-
DESCRIPTION- SINGH ET AL., J. ORG. CHEM., (1998), vol. 63, pages 10035 - 10039-
DESCRIPTION- SMITH; WATERMAN, ADV. APPL. MATH., (1981), vol. 2, pages 482 - 489-
DESCRIPTION- SRIVASTAVA ET AL., J. AM. CHEM. SOC., (2007), vol. 129, no. 26, pages 8362 - 8379-
DESCRIPTION- TILLY ET AL., J. LIPID RES., (2003), vol. 44, pages 430 - 436-
DESCRIPTION- TOSKES, GASTROENTEROL CLIN NORTH AM, (1990), vol. 19, pages 783 - 791-
DESCRIPTION- TREMBLAY ET AL., J CLIN LIPIDOL, (2011), vol. 5, pages 37 - 44-
DESCRIPTION- VU-DAC ET AL., J. CLIN. INVEST., (1998), vol. 102, pages 625 - 632-
DESCRIPTION- WAHLESTEDT ET AL., PROC. NATL. ACAD. SCI. U. S. A., (2000), vol. 97, pages 5633 - 5638-
DESCRIPTION- WATERWORTH ET AL., ARTERIOSCLER THROMB VASC BIOL, (2000), vol. 20, pages 2663 - 2669-
DESCRIPTION- WEISSGLAS-VOLKOV; PAJUKANTA, J LIPID RES, (2010), vol. 51, pages 2032 - 2057-
DESCRIPTION- WOOLF ET AL., PROC. NATL. ACAD. SCI. USA, (1992), vol. 89, pages 7305 - 7309-
DESCRIPTION- YUAN ET AL., CMAJ, (2007), vol. 176, pages 1113 - 1120-
DESCRIPTION- ZHANG; MADDEN, GENOME RES., (1997), vol. 7, pages 649 - 656-
EXAMINATION- FAHIE-WILSON M ET AL, "HDL cholesterol and the acute phase reaction following myocardial infarction and acute pancreatitis", CLINICA CHIMICA ACTA, ELSEVIER BV, AMSTERDAM, NL, vol. 167, no. 2, doi:10.1016/0009-8981(87)90372-X, ISSN 0009-8981, (19870814), pages 197 - 209, (19870814), XP023397692
INTERNATIONAL-SEARCH-REPORT- HERNANDEZ ET AL., "Regulation of hepatic ApoC3 expression by PGC-1 beta mediates hypolipidemic effect of nicotinic acid.", CELL. METAB., (20101006), vol. 12, no. 4, pages 411 - 419, XP055135947
INTERNATIONAL-SEARCH-REPORT- DE GROOTH ET AL., "A review of CETP and its relation to atherosclerosis.", J. LIPID RES., (200411), vol. 45, no. 11, pages 1967 - 1974, XP055135945
INTERNATIONAL-SEARCH-REPORT- YUAN ET AL., "Hypertriglyceridemia: its etiology, effects and treatment.", CMAJ., (20070410), vol. 176, no. 8, pages 1113 - 1120, XP055135946
OPPOSITION- JONG et al., "Apolipoprotein C-111 deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice", J. Lipid Res., (20011000), vol. 42, no. 10, pages 1578 - 1585, XP055527006-
OPPOSITION- KADIKOYLU et al., "Emergent therapy with therapeutic plasma exchange in acute recurrent pancreatitis due to severe hypertriglyceridemia", Transfusion and Apheresis Science, (20101124), vol. 43, pages 285 - 289, XP027525519-
OPPOSITION- MAEDA et al., "Targeted Disruption of the Apolipoprotein C-III Gene in Mice Results in Hypotriglyceridemia and Protection from Postprandial Hypertriglyceridemia", J Biol Chem., (19940900), vol. 269, no. 38, pages 23610 - 23616, XP002508088-
OPPOSITION- SUBRAMANIAM A. et al., "954-P: ApoC-111 Antisense Oligonucleotides Reduce Liver mRNA and Scrum Triglyceride Levels ln Hypertriglyceridemic Rats", ADA Abstract, (20050000), page A233, XP008161449-
OPPOSITION- FAHIE-WILSON et al., "HDL cholesterol and the acute phase reaction following myocardial infarction and acute pancreatitis", Clinica Chimica Acta, (19870814), vol. 167, no. 2, pages 197 - 209, XP023337268
OPPOSITION- LINCOFF et al., "Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease", N Engl J Med, (20170518), vol. 376, no. 20, pages 1933 - 1942, XP055527018
OPPOSITION- STAELS et al., "Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates", J Clin Invest., (19950200), vol. 95, no. 2, pages 705 - 712, XP001029873
OPPOSITION- CROOKE, "Antisense oligonucleotides as therapeutics for hyperlipidaemias", Expert Opinion on Biological Therapy, (20050700), vol. 5, no. 7, pages 907 - 917, XP009075941
SEARCH- GRAHAM MARK J ET AL, "Antisense Inhibition of ApoC-III in Rhesus Monkeys Reduces Plasma Triglycerides and Raises HDL-C Without Increasing Hepatic Fat", CIRCULATION RESEARCH, & AMERICAN-HEART-ASSOCIATION SCIENTIFIC SESSIONS ON RESUSCITATION SCIENCE SYMPOSIUM; ORLANDO, FL, USA; NOVEMBER 12 -16, 2011, (201112), vol. 109, no. 12, page E60, XP009180729 [IP] 1-15 * abstract *-
SEARCH- MAEDA NOBUYO ET AL, "Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, (19940923), vol. 269, no. 38, ISSN 0021-9258, pages 23610 - 23616, XP002508088 [Y] 1-15 * abstract *-
SEARCH- SUBRAMANIAM AMUTHAKANNAN ET AL, "ApoC-III antisense Oligonucleotides reduce liver mRNA and serum triglyceride levels in hypertriglyceridemic rats", vol. 54, no. Suppl. 1, ISSN 0012-1797, (20050101), page 1, DIABETES; 65TH ANNUAL MEETING OF THE AMERICAN-DIABETES-ASSOCIATION, AMERICAN DIABETES ASSOCIATION, US; SAN DIEGO, CA, USA, URL: http://diabetes.diabetesjournals.org/, (20141014), XP008161449 [Y] 1-15 * abstract *-
SEARCH- POLLIN TONI I ET AL, A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection., SCIENCE (NEW YORK, N.Y.) 12 DEC 2008, VOL. 322, NR. 5908, PAGE(S) 1702 - 1705, (20081212), ISSN 1095-9203, XP002731095 [Y] 1-15 * abstract *
SEARCH- M. J. GRAHAM ET AL, "Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans", CIRCULATION RESEARCH, (20130329), vol. 112, no. 11, doi:10.1161/CIRCRESAHA.111.300367, ISSN 0009-7330, pages 1479 - 1490, XP055146075
SEARCH- MULLICK ADAM E ET AL, Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice., JOURNAL OF LIPID RESEARCH MAY 2011, VOL. 52, NR. 5, PAGE(S) 885 - 896, (201105), ISSN 0022-2275, XP002731099 [YP] 1-15 * abstract *
SEARCH- CROOKE R M, "Antisense oligonucleotides as therapeutics for hyperlipidaemias", EXPERT OPINION ON BIOLOGICAL THERAPY,, (20050701), vol. 5, no. 7, doi:10.1517/14712598.5.7.907, ISSN 1471-2598, pages 907 - 917, XP009075941 [Y] 1-15 * Paragraph 7.3 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents